Wu Ling, Huang Xiangping, Ouyang Qianhui, Liu Wen, Liu Sixiang, Huang Ying, Peng Ya, Ning Ding, Tan Chaochao
Department of Clinical Laboratory, The First Affiliated Hospital of Hunan Normal University (Hunan Provincial People's Hospital), Changsha, Hunan, China.
Department of Pharmacy, The First Affiliated Hospital of Hunan Normal University (Hunan Provincial People's Hospital), Changsha, Hunan, China.
Clin Chim Acta. 2023 Feb 15;541:117251. doi: 10.1016/j.cca.2023.117251. Epub 2023 Feb 10.
BACKGROUND & AIMS: Chronic pancreatitis (CP) is an inflammatory disease characterized by irreversible changes. However, acute CP attacks can lead to various complications and affect patient prognosis. Therefore, this study aimed to identify reliable candidate metabolic biomarkers for diagnosing acute CP attacks and complement candidate diagnostic markers for CP.
A total of 139 serum specimens were prospectively included in three consecutive exploratory, identification, and validation studies. All samples were analyzed for candidate diagnostic biomarkers and metabolic pathways using a liquid chromatography-mass spectrometer.
Serum metabolic profiles differed between patients with CP and non-pancreatic disease controls, and 239 potential metabolic biomarkers for diagnosing CP were identified. Based on identification and validation studies, Diacylglycerol(16:0/18:4), 16-F1-PhytoP, N-(hexacosanoyl)-tetradecasphing-4-enine, carnosic acid, and Auxin b were identified as biomarkers for distinguishing acute attacks from non-acute attacks in patients with CP. The area under the curve of the Diacylglycerol(16:0/18:4) was 0.969 (95% confidence interval, 0.869-1) in the validation study.
To the best of our knowledge, this is the first prospective cohort study to identify and validate a metabolomic signature in serum for diagnosing acute attacks of CP. In addition, our study identified 239 potential biomarkers for CP diagnosis.
慢性胰腺炎（CP）是一种以不可逆改变为特征的炎症性疾病。然而，急性CP发作可导致各种并发症并影响患者预后。因此，本研究旨在识别用于诊断急性CP发作的可靠候选代谢生物标志物，并补充CP的候选诊断标志物。
在三项连续的探索性、识别性和验证性研究中前瞻性纳入了总共139份血清标本。使用液相色谱 - 质谱仪对所有样本进行候选诊断生物标志物和代谢途径分析。
CP患者与非胰腺疾病对照组的血清代谢谱不同，共识别出239种用于诊断CP的潜在代谢生物标志物。基于识别和验证研究，二酰基甘油（16:0/18:4）、16 - F1 - 植物磷酸、N - （二十六烷酰基） - 十四碳鞘氨醇 - 4 - 烯、肌醇六磷酸和生长素b被确定为区分CP患者急性发作与非急性发作的生物标志物。在验证研究中，二酰基甘油（16:0/18:4）的曲线下面积为0.969（95%置信区间，0.869 - 1）。
据我们所知，这是第一项前瞻性队列研究，旨在识别和验证血清中的代谢组学特征以诊断CP的急性发作。此外，我们的研究还识别出239种用于CP诊断的潜在生物标志物。
